uniQure (NASDAQ:QURE) Trading Down 7.8% – Should You Sell?

uniQure N.V. (NASDAQ:QURE)’s share price was down 7.8% on Thursday . The company traded as low as $26.83 and last traded at $26.8950. Approximately 905,115 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 2,857,977 shares. The stock had previously closed at $29.17.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on QURE shares. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a research note on Tuesday, May 5th. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $11.00 to $35.00 in a research note on Monday, March 9th. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Finally, Barclays decreased their price target on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.83.

uniQure Price Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The stock’s 50 day simple moving average is $18.31 and its two-hundred day simple moving average is $23.59. The firm has a market capitalization of $1.71 billion, a PE ratio of -7.77 and a beta of 0.87.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. On average, sell-side analysts forecast that uniQure N.V. will post -3.68 EPS for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 14,581 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $132,103.86. Following the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at $5,985,561.48. This trade represents a 2.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Christian Klemt sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the transaction, the chief financial officer directly owned 226,581 shares in the company, valued at $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 94,396 shares of company stock valued at $1,850,434. Company insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp increased its holdings in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 5.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of uniQure by 6.0% during the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after buying an additional 627 shares during the last quarter. Ensign Peak Advisors Inc increased its holdings in shares of uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after buying an additional 650 shares during the last quarter. Finally, FNY Investment Advisers LLC increased its holdings in shares of uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.